RZLT Stock Plummets 79% Month to Date: Here's What You Need to Know

Key Takeaways Rezolute stock plunged after phase III data showed ersodetug failed to meet the primary goal in the HI study.RZLT's top dose cut HI events ~45%, but placebo improved ~40%, leaving results not statistically significant.RZLT is reviewing data, planning FDA talks, and advancing ersodetug in tumor-induced HI via the upLIFT study.Shares of Rezolute (RZLT) have plummeted 79.2% so far in December. The massive stock price crash was observed after RZLT reported disappointing top-line data from a late-s ...